학술논문
The combination of EGFR-TKIs and anlotinib as a first-line therapy for EGFR-mutant advanced non-small cell lung cancer: A multicenter, single-arm, phase II clinical trial.
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
15277755